Evidence map›Paper›PMID 31137460›Full record

ArticleInternational journal of molecular sciences2019

Differential Effects of a Full and Biased Ghrelin Receptor Agonist in a Mouse Kindling Model.

An Buckinx, Yana Van Den Herrewegen, Anouk Pierre, Eleonora Cottone, Khoubaib Ben Haj Salah, Jean-Alain Fehrentz, Ron Kooijman, Dimitri De Bundel, Ilse Smolders

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

An BuckinxDepartment of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Research Group Experimental Pharmacology, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium. an.buckinx@vub.be.
Yana Van Den HerrewegenDepartment of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Research Group Experimental Pharmacology, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium. Yana.Van.Den.Herrewegen@vub.be.
Anouk PierreDepartment of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Research Group Experimental Pharmacology, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium. anouk.pierre@vub.be.
Eleonora CottoneDepartment of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Research Group Experimental Pharmacology, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium. Eleonora.cottone@vub.be.
Khoubaib Ben Haj SalahMax Mousseron Institute of Biomolecules UMR524, CNRS, University of Montpellier, Ecole Nationale Supérieure de Chimie de Montpellier, 34090 Montpellier, France. khoubaib.bhs@gmail.com.ORCID 0000-0002-2313-2773
Jean-Alain FehrentzMax Mousseron Institute of Biomolecules UMR524, CNRS, University of Montpellier, Ecole Nationale Supérieure de Chimie de Montpellier, 34090 Montpellier, France. jean-alain.fehrentz@univ-montp1.fr.ORCID 0000-0002-6064-3118
Ron KooijmanResearch Group Experimental Pharmacology, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), 1050 Brussels, Belgium. ron.kooijman@vub.be.
Dimitri De BundelDepartment of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Research Group Experimental Pharmacology, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium. dimitri.de.bundel@vub.be.
Ilse SmoldersDepartment of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Research Group Experimental Pharmacology, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium. Ilse.smolders@vub.be.
Vrije Universiteit Brussel · BEÉcole Nationale Supérieure de Chimie de Montpellier · FR

Funding

Fonds Wetenschappelijk Onderzoek 1S84218NGeneeskundige Stichting Koningin Elisabeth ING-prizeWetenschappelijk Fonds Willy Gepts N/A
6 · The paper itself

Abstract

The ghrelin system has received substantial recognition as a potential target for novel anti-seizure drugs. Ghrelin receptor (ghrelin-R) signaling is complex, involving Gα

Indexed as

Kindling, NeurologicAnimalsBenzazepinesbeta-ArrestinsBrainDopamine AgonistsGlycineIndolesMaleMiceMice, Inbred C57BLPiperidinesQuinazolinonesReceptors, GhrelinTriazolesTryptophanBenzazepinesbeta-ArrestinsDopamine AgonistsGlycineIndolesmacimorelinN-(1-(4-(4-methoxybenzyl)-5-phenethyl-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethyl)-2-aminoacetamidePiperidinesQuinazolinonesReceptors, GhrelinSK&F 81297TriazolesTryptophanYIL 781biased signalingepilepsyghrelin receptorJMV-1843JMV-2959YIL781β-arrestin

Identifiers

PMID31137460
PMCPMC6567032
OpenAlexW2946255548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.